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Several studies have been carried out to evaluate the alterations in mitochondrial functions of diabetic rats. However, results are sometimes
controversial, since experimental conditions diverge, including age and strain of used animals. The purpose of this study was to evaluate the
metabolic modifications in liver mitochondria, both in the presence of severe (STZ-treated rats) and mild hyperglycaemia [Goto–Kakizaki
(GK) rats], when compared with control animals of similar age. Moreover, metabolic alterations were evaluated also at initial and advanced
stages of the disease.
We observed that both models of diabetes (type 1 and type 2) presented a decreased susceptibility of liver mitochondria to the induction of
permeability transition (MPT). Apparently, there is a positive correlation between the severity of diabetes mellitus (and duration of the disease)
and the decline in the susceptibility to MPT induction. We also found that liver mitochondria isolated from diabetic rats presented some
metabolic adaptations, such as an increase in coenzyme Q and cardiolipin contents, that can be responsible for the observed decrease in the
susceptibility to multiprotein pore (MPTP) opening.
D 2003 Published by Elsevier B.V.Keywords: Diabetes mellitus; Type 1 diabetes; Type 2 diabetes; Goto–Kakizaki (GK) rat; Streptozotocin-induced diabetic (STZ) rat; Mitochondrial
permeability transition (MPT)1. Introduction
In higher animals, mitochondria play an essential role in
cellular energy metabolism since most of the ATP is pro-
duced by mitochondrial oxidative phosphorylation. There-
fore, it is essential to have mitochondria intimately involved
in metabolic regulation and maintenance of ATP production
efficiency [1,2].
The inner mitochondrial membrane (IMM) possesses an
intrinsically low permeability to ions and solutes, allowing
energy conservation in the form of a proton electrochemical
potential difference. The IMM also possesses a set of
channels and transporters that regulate ion fluxes across
the membrane since this management is essential for both
metabolic regulation and energy conservation.0925-4439/$ - see front matter D 2003 Published by Elsevier B.V.
doi:10.1016/j.bbadis.2003.08.001
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826798.
E-mail address: mssantos@ci.uc.pt (M.S. Santos).Another important role for mitochondria is the calcium
buffering capacity, avoiding excessive cytosolic calcium
accumulation. Mitochondrial calcium uptake also controls
the activity of Ca2 +-sensitive dehydrogenases and other
metabolic processes. In the presence of high external Ca2 +
concentrations, isolated mitochondria can easily undergo an
increased permeability to solutes with molecular masses up
to 1500 kDa. This event is called the mitochondrial perme-
ability transition (MPT) and is caused by the opening of
multiprotein pore (MPTP) formed by several proteins of the
outer and IMM, including the voltage-dependent anion
channel (VDAC), the adenine nucleotide translocator
(ANT) and the matrix protein cyclophilin [3,4]. MPTP
opening can be induced by increasing amounts of Ca2 +
and oxidative stress.
Previous studies have focused in abnormalities in the
MPT during diabetes [5,6], as well as changes in mitochon-
drial bioenergetics and antioxidant defences [7–9].
Diabetes mellitus is a common degenerative disease and
one of the leading causes of morbidity and mortality in
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erogeneous disease, with a common phenotype of impaired
glucose tolerance and, depending on the basis of the man-
agement required to control glucose homeostasis, it can be
divided into type 1 and type 2 diabetes [10–12].
With the purpose of understanding the physiological and
pathological changes in this complex disease, animal models
for diabetes are important research tools since they allow for
a tight control over experimental conditions, almost impos-
sible to achieve in human populations [13,14]. In the present
study, two animal models for diabetes were used in order to
study abnormalities in liver MPT. STZ-induced diabetic rats,
commonly used as an animal model for type 1 diabetes
mellitus, were obtained after selective destruction of h-cells
by streptozotocin (STZ), a broad-spectrum antibiotic with
diabetogenic effects. STZ-injected rats present many char-
acteristics seen in insulin-dependent diabetic human patients:
hypoinsulinemia, hyperglycaemia, ketonuria and hyperlipi-
daemia [13,15]. Goto–Kakizaki (GK) rats are currently used
as a non-obese animal model of type 2 diabetes mellitus [16],
obtained by selective breeding of normal Wistar rats, using
glucose intolerance as selection index [17–19].
In the present study we investigated the impact of diabetes
mellitus on mitochondrial calcium fluxes and on the MPT
susceptibility in the presence of Ca2 +/Pi both in STZ and GK
rats. The study was conducted during the progression of
diabetes, with the purpose of assessing the mitochondrial
metabolic modifications in liver mitochondria. As much as
we know, no reports were available concerning mitochon-
drial alterations in calcium handling during the progression
of the disease in the two described models. Our results
showed that in liver mitochondria diabetes decreased the
susceptibility to the induction of MPT.2. Materials and methods
2.1. Materials
Streptozotocin [2-deoxy-2-(3-methyl-3-nitrosurea) 1-D-
glucopyranose] was obtained from Sigma Chemical Co.
(St. Louis, MO, USA), and prepared prior to use in 100
mM citrate, pH 4.5. Calcium Green 5-N was obtained from
Molecular Probes (Eugene, OR, USA). All other reagents
and chemicals used were of the highest grade of purity
commercially available.
2.2. Animals
Spontaneously diabetic male GK rats, 13 or 20 weeks of
age, were obtained from our local breeding colony (Animal
Research Center Laboratory, University Hospitals, Coim-
bra), established in 1995 with breeding couples from the
colony at the Tohoku University School of Medicine (Sen-
dai, Japan; courtesy of Dr. K. Susuki). Control animals were
non-diabetic male Wistar rats of similar age.Animals were kept under controlled light (12-h day/night
cycle), temperature (22–24 jC) and humidity (50–60%)
conditions and with free access to powdered rodent chow
(diet URF1, Charles Rivers, France) and water (pH 5.5),
except during the fasting periods. In this study, the ‘‘Princi-
ples of Laboratory Animal Care’’ (NIH publication 83-25,
revised 1985) were followed. During this period glycaemia
was determined from the tail vein using a commercial
glucometer (Glucometer-Elite, Bayer).
2.3. Induction and characterization of STZ-induced
diabetes
Male Wistar rats weighing about 200 g (10 weeks) were
randomly divided into two groups of 10 animals each. In
order to induce diabetes, one group was injected intraper-
itoneally with a single injection of streptozotocin (STZ, 50
mg/kg), after a 16-h fasting period. The volume used was
always 0.5 ml/200 g body weight. Control animals were
injected with the same volume of citrate solution. In the
following 24 h, animals were orally feed with glycosilated
serum in order to avoid hypoglycaemia resulting from
massive destruction of ß-cells and release of intracellular
insulin associated with STZ treatment [13]. Animals were
kept 3 or 9 weeks before the experiments. In this study, in
order to avoid another variability factor than diabetes, we
used two groups of animals with similar age: 13 weeks of age
in one group (STZ-treated rats with 3 weeks after treatment,
GK rats 13 weeks of age and control rats with similar age,
Wistar rats with 3 weeks after injection with vehicle and/or
13 weeks of age) and 19–20 weeks of age in the other group
(STZ-treated rats with 9 weeks after treatment, GK rats 20
weeks of age and control group with similar age, Wistar with
9 week after injection with vehicle and/or 20 weeks of age.
Our results show that intravenous administration of citrate
does not modify the parameters studied.
During this period, weight was measured and glycaemia
was determined from the tail vein as described before. Values
were taken in fasting conditions just before STZ administra-
tion and in non-fasting conditions in the weeks after. If
feeding blood glucose in the tail vein exceeded 250 mg/dl,
animals were used as diabetic.
2.4. Glycaemia and HbA1C evaluation
Blood glucose concentration was determined immediate-
ly after animal sacrifice (Glucometer-Elite, Bayer). The
glycated hemoglobin (HbA1C) values were determined in
blood collected at the time of animals’ death through ionic
exchange chromatography (Abbott Imx Glicohemoglobin,
Abbott Laboratories, Portugal).
2.5. Preparation of liver mitochondria
Mitochondria were isolated from the livers of normal and
diabetic rats (maintained ad libitum for at least 12 h before
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method [20], with slight modifications.
Homogenization medium contained 210 mM mannitol,
70 mM sucrose, 5 mM HEPES (pH 7.4), 0.2 mM EGTA, 0.1
mM EDTA and 0.1% defatted bovine serum albumin (BSA).
EDTA, EGTA and defatted BSAwere omitted from the final
washing medium and adjusted to pH 7.2. The mitochondrial
pellet was washed twice, suspended in the washing medium
and immediately used. Protein was determined by the biuret
method, using BSA as a standard [21].
2.6. Membrane potential (DW) measurements
The mitochondrial transmembrane potential was estimat-
ed by calculating transmembrane distribution of tetraphe-
nylphosphonium ion (TPP+) with a TPP+-selective
electrode, prepared as previously reported [22], using a
calomel electrode as a reference. TPP+ uptake was mea-
sured from the decrease in TPP+ concentration in the
medium. The potential difference between the selective
and the reference electrodes was measured with an elec-
trometer and continuously recorded. A matrix mitochondri-
al volume of 1.1 Al/mg was assumed and valinomycin was
used to calibrate the baseline. Reactions were carried out at
25 jC in 1 ml of the reaction media (200 mM sucrose, 10
mM Tris–Cl, 10 AM EGTA, 1 mM KH2PO4, pH 7.2),
supplemented with 3 AM TPP+, 2 AM rotenone and 0.1 Ag
oligomycin, 1 mg mitochondria and 5 mM succinate. The
calcium accumulation capacity was determined by adding
small pulses of CaCl2 (10 nmol/mg protein each); these
small amounts of calcium were added until the opening of
MPTP was observed (as an irreversible drop in DWm).
2.7. Measurement of mitochondrial Ca2+ fluxes
The uptake and following release of Ca2 + by isolated
mitochondria was evaluated with the hexapotassium salt of
the calcium-sensitive fluorescent probe Calcium Green 5-N,
according to Oliveira et al. [23]. The reactions were carried
out in 2 ml of reaction medium (200 mM sucrose, 10 mM
Tris–Cl, 10 AM EGTA, 1 mM KH2PO4; pH 7.2), supple-
mented with 0.6 mg liver mitochondria, 2 AM rotenone, 0.1
Ag oligomycin, 5 mM succinate and 100 nM Calcium
Green 5-N, and stirred continuously in a water-jacketed
cuvette holder at 25 jC. Fluorescence was continuously
monitored with a Perkin-Elmer LS-50B spectrofluorometer
(excitation 506 nm and emission 531 nm), for 50 s, prior to
the addition of Ca2 + (33 nmol/mg protein). Excess EGTA
was used to stop the reaction and to obtain the baseline. As
the addition of Ca2 + produced a different peak in control
and diabetic rats (probably, due to different cardiolipin
contents in mitochondrial inner membrane), the data were
‘corrected’ based on the ratio of these peaks [(1/mean value
of Wistar peaks) 100]; this correction was performed to
each different pair of mitochondrial preparations (diabetic
and control). Calcium fluxes were expressed as arbitraryunits of fluorescence (AFU), determined 100 and 210 s
after the addition of Ca2 +.
2.8. Extraction and quantification of coenzyme Q
Aliquots of mitochondria containing 2 mg protein/ml
were extracted according to the method described previously
[24]. The extract was evaporated to dryness under a stream of
N2, and stored at  80 jC, for HPLC analysis. Liquid
chromatography was performed using a Gilson HPLC appa-
ratus with a reverse phase column (RP18; Spherisorb; S5
ODS2), as described by Chung et al. [25]. Samples were
eluted from the column with methanol/heptane (10:2 v/v) at a
flow rate of 2 ml/min. Detection was performed using a UV
detector at 269 nm. Identification and quantification were
based on pure standards by their retention times and peak
areas, respectively. The levels of coenzyme Q (CoQ9 and
CoQ10) were expressed in pmol/mg protein.
2.9. Quantification of cardiolipin content
Mitochondrial cardiolipin content was quantified using
an established spectrophotometric assay using 10-nonyl-
acridine orange (NAO) [26]. Briefly, rat liver mitochondria
(0.25 mg protein/ml) were suspended in 210 mM mannitol,
70 mM sucrose, 5 mM HEPES (pH 7.2). Aliquots of this
suspension (150 Al) were added to increasing amounts of
NAO (1–25 AM) and the final volume adjusted to 1.5 ml
with the suspension buffer. The samples were incubated for
5 min at room temperature and then centrifuged at
35,000 g for 5 min, using a Beckman ultracentrifuge
(model TL-100 and TL-100 rotor). The pellets were dis-
carded and the amount of unbound NAO in the supernatant
was measured spectrophotometrically at 495 nm. A standard
curve was generated using NAO (1–25 AM) in the absence
of mitochondria. The number of moles of NAO per milli-
gram of protein was calculated by subtracting the sample
absorbance (unbound NAO) from the value of absorbance
correspondent in standard curve (full amount of NAO) [27].
Cardiolipin content was calculated as the half of this value
due to the 2:1 stoichiometric relationship between NAO and
cardiolipin [27].
2.10. Citrate synthase assay
Citrate synthase was determined according to Coore et al.
[28]. Briefly, freeze-thawed liver mitochondria (100 Ag)
were incubated with 1 ml of Tris-based media [100 mM
Tris, 200 AM Acetyl-CoA and 200 AM DTNB (5,5V-dithio-
bis-2-nitrobenzoic acid)]. The absorbance of the suspension
was continuously measured at 412 nm under stirring and at
25 jC. After a basal line setting, 100 AM oxaloacetate was
added. In this protocol, we measured the formation rate of a
coloured product resulting from the condensation of DTNB
and coenzyme A. Our results did not show any significant
difference between citrate synthase contents, thus pointing
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dria per milligram of protein in control and diabetic (GK and
STZ) rats.
2.11. Statistic analysis of data
The results are presented as meanF S.E. of the number
of experiments indicated and statistical significance between
diabetic rats and their control group was determined using
unpaired Student’s t test. Multiple comparison was per-
formed using one-way ANOVA, with the Student–New-
man–Keuls as a post-test. P < 0.05 was considered
significant.Fig. 1. Calcium accumulation capacity of liver mitochondria isolated from
Wistar control and diabetic rats: The Ca2 + accumulation capacity, measured
with a TPP+ selective electrode, was determined by adding several pulses of
CaCl2 (10 nmol/mg protein each), in order to induce MPT. The MPTP
opening was assessed as a drop in membrane potential. In the presence of
cyclosporin A, a specific inhibitor of MPT induction, the number of pulses
of calcium needed to induce a similar decrease membrane potential is much
higher (both for diabetic and control mitochondrial preparations, not shown).
The traces are representative of experiments performed with different
mitochondrial preparations.3. Results
3.1. Characterization of animals
Blood glucose levels, determined immediately after the
sacrifice of the animals, were significantly higher in diabetic
rats when compared to controls (Table 1). However, GK rats
presented mild hyperglycaemia (120–210 mg/dl), while
STZ-treated rats presented severe hyperglycaemias (>380
mg/dl). In order to estimate the severity of diabetes, glycated
hemoglobin (HbA1c) was also evaluated since HbA1c is a
very useful parameter to evaluate the severity of diabetes,
indicating the average blood glucose levels presented 2–3
months prior to the analysis. The determined levels of HbA1c
(Table 1) confirmed that blood glucose levels were signifi-
cantly increased in diabetic rats and these levels in STZ-
treated rats were also significantly augmented as compared
to GK rats.
3.2. Calcium accumulation capacity
Calcium accumulation capacity of liver mitochondria
from diabetic and control rats was determined observingTable 1
Characterization of animals
Condition 3 weeks after treatment 9 weeks after treatment
Wistar STZ Wistar STZ
Glycaemia
(mg/dl)
115.1F 4.5
(n= 6)
409.3F 17.9
(n= 6)***, #,&&
97.3F 5.5
(n= 6)
468.6F 15
(n= 6) ***
HbA1C 5.23F 0.21
(n= 6)
10.25F 0.43
(n= 6)***, #,&&
5.84F 0.47
(n= 6)
11.71F 0.3
(n= 6) ***
Data are meanF S.E. obtained from the number of samples indicated, each obt
described in Materials and methods.
* P < 0.05 as compared to controls.
** P < 0.01 as compared to controls.
*** P < 0.001 as compared to controls.
# P < 0.05 compared with STZ (9 weeks after treatment).
## P< 0.01 compared with STZ (9 weeks after treatment).
### P < 0.001 compared with STZ (9 weeks after treatment).
& P< 0.05 compared with GK (20 weeks of age).
&& P< 0.01 compared with GK (20 weeks of age).the effect of known amounts of calcium (‘pulses’ of 10
nmol CaCl2 each) in the mitochondrial DW (Fig. 1 and
Table 2). Mitochondria possess a finite capacity for accu-
mulating calcium before undergoing the calcium-dependent
MPT. Our results showed that liver mitochondria from
diabetic rats were able to accumulate a higher amount of
added Ca2 +. Therefore, liver mitochondria isolated from
diabetic rats could handle a larger number of pulses of
calcium (5 to 11 pulses of 10 nmol Ca2 +/mg protein)
compared to Wistar rats (about 4 pulses of 10 nmol Ca2 +/
mg protein; see Fig. 1 for typical experiment) before the
irreversible drop in DW, compatible with the MPTP open-
ing. This decline in DW was abolished in the presence of13 weeks of age 20 weeks of age
Wistar GK Wistar GK
.6
,&&
101.3F 5.0
(n= 8)
141.2F 9.4
(n= 8) *, ###, &
85.7F 5.0
(n= 9)
162.0F 28.6
(n= 9)*, ##
9
,&&
5.04F 0.12
(n= 6)
7.32F 0.67
(n= 6)*, ##
5.43F 0.33
(n= 6)
8.46F 0.89
(n= 6)**, ##
ained from a different animal. Glycaemia and HbA1C were determined as
Table 2
Effect of diabetes on Ca2 + accumulation capacity
Condition DWm (mV) DWm (mV)
(after 3 pulses of
10 nmol Ca2 +)
Pulses of Ca2 +
(mean value)
Wistar
(3 weeks
after treatment)
225.0F 1.20
(n= 6)
219.9F 3.13
(n= 6)
4.70F 0.62
(n= 6)###
STZ
(3 weeks
after treatment)
228.2F 1.61
(n= 6)
223.3F 0.65
(n= 6)
5.50F 0.29
(n= 6)*, ###
Wistar
(9 weeks
after treatment)
223.1F 2.96
(n= 6)
218.2F 1.37
(n= 6)
4.59F 0.22
(n= 6)
STZ
(9 weeks
after treatment)
230.6F 2.46
(n= 6)*
227.3F 2.74
(n= 6)*
11.20F 0.70
(n= 6)***
Wistar
(13 weeks
of age)
220.6F 2.00
(n= 7)
215.8F 2.95
(n= 8)
3.62F 0.19
(n= 7)###
GK
(13 weeks
of age)
225.0F 1.12
(n= 7)&&&
222.2F 1.37
(n= 7)
5.56F 0.45
(n= 7)*, ##
Wistar
(20 weeks
of age)
222.6F 2.45
(n= 8)
212.5F 2.55
(n= 8)
4.00F 0.22
(n= 8)###
GK
(20 weeks
of age)
235.8F 1.99
(n= 8)***
228.0F 1.86
(n= 8)***
5.62F 0.28
(n= 8)*, ###
The mitochondrial electric potential measurements (DW) were performed
with a TPP+ selective electrode. DW was evaluated as described in Materials
and methods. Data are meanF S.E. of the number of independent
experiments indicated, performed with at least three different mitochondrial
preparations.
* P< 0.05 compared to controls.
*** P < 0.001 compared to controls.
## P < 0.01 compared to STZ (9 weeks after treatment).
### P < 0.001 compared to STZ (9 weeks after treatment).
&&& P< 0.001 compared to GK (20 weeks of age).
Fig. 2. Mitochondrial Ca2 + fluxes in liver mitochondria isolated from
diabetic and Wistar control rats: (A) Typical measurements of calcium
movements using the fluorescent calcium sensitive probe Calcium Green 5-
N, as described in Materials and methods. The reactions were carried out in
2 ml of reaction medium supplemented with 0.6 mg protein, 2 AM
rotenone, 0.1 AM oligomycin, 5 mM succinate and 100 nM Calcium Green
5-N. Fluorescence was monitored continuously for 50s, prior to the addition
of 33 nmol Ca2 +/mg protein, and stopped with excess EGTA to obtain the
baseline. The calcium release was inhibited by 0.8 AM cyclosporin A,
indicating that the observed release was due to MPTP opening. Calcium
fluxes are expressed as arbitrary units of fluorescence (AFU), determined
100s (B) and 210s (C) after the addition of 33 nmol Ca2 +/mg protein, as
described in Materials and methods. Data are meanF S.E. of four
independent experiments performed with different mitochondrial prepara-
tions. *P < 0.05, **P < 0.01, ***P< 0.001, as compared to Wistar control
rats.
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shown).
Previous results, showing the higher calcium capacity of
diabetic mitochondria, were confirmed by determinations of
extramitochondrial calcium movements, using the fluores-
cent calcium-sensitive probe Calcium Green 5-N. The addi-
tion of Ca2 + leads to an increase of the Ca2 + content in the
external medium, which is associated to the rapid increase in
fluorescence (the first peak in Fig. 2A). As the calcium is
accumulated by mitochondria, the fluorescence decreases.
The MPTP opening leads to the release of the previous
accumulated calcium and consequently to an increase in
fluorescence. The release of calcium was completely abol-
ished (both in Wistar and diabetic rat liver mitochondria) by
cyclosporine A, indicating that the release was due to MPTP
opening (Fig. 2A). We observed that 100 s after the addition
of calcium (33 nmol CaCl2/mg protein), the Ca
2 + loss by
diabetic liver mitochondria was significantly lower when
compared to control Wistar rats (Fig. 2B). Moreover, 210 s
after the addition of Ca2 +, the release of calcium was
significantly decreased in diabetic rats (except for GK ratswith 13 weeks of age) compared to controls (Fig. 2C).
Therefore, our results indicated that mitochondrial calcium
Fig. 3. Coenzyme Q content in liver mitochondria isolated from Wistar
control and diabetic rats. The levels of coenzyme Q (CoQ9 and CoQ10) were
measured by HPLC as described in Materials and methods and expressed in
pmol/mg protein. Data are meanF S.E. of five different mitochondrial
preparations. ***P< 0.001 as compared to Wistar control rats.
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tes severity.
3.3. Mitochondrial CoQ content
CoQ in rat mitochondria consists of two main homo-
logues, CoQ9 and CoQ10. In Wistar non-diabetic rats, CoQ10
represented 10–16% of the total amount of mitochondrial
CoQ, while in diabetic rats this ratio varied between 8% and
12%. However, the amount of CoQ, particularly CoQ9, was
significantly increased in liver mitochondria isolated from
diabetic rats (up to 2.5-fold) (Fig. 3). Results of citrate
synthase quantification and analysis by electron microscopy
(data not shown) showed that the contamination level ofFig. 4. Cardiolipin content in liver mitochondria isolated from diabetic and Wis
established spectrophotometric assay using 10-NAO, as described in Materials and
$$P < 0.01,$$$P < 0.001, compared to STZ 3 weeks after treatment; *P < 0.05. **P
STZ); #P< 0.05 as compared to Wistar 20 weeks of age (9 weeks after treatmentmitochondrial preparations was very low. Therefore, the
contents of CoQ determined can be attributed to the IMM.
3.4. Mitochondrial cardiolipin content
In order to help in the understanding of the observed
resistance of diabetic mitochondria to MPT induction, car-
diolipin (diphosphatidylglycerol) contents were evaluated
[26]. Our results showed that liver mitochondria isolated
from diabetic rats presented a significantly higher content of
cardiolipin, except for the STZ-treated rats, 3 weeks after
STZ treatment (Fig. 4).4. Discussion
Mitochondria are the major ATP producer in eukaryotic
mammalian cells and also the main intracellular sources and
target of reactive oxygen species (ROS). Moreover, mito-
chondria play an important role in the regulation of intracel-
lular Ca2 + homeostasis. Previous reports describe some
abnormalities in MPTP associated with diabetes [5,6]. Since
the opening of MPTP can be induced by increasing amounts
of Ca2 + and by oxidative stress, and considering that
diabetes leads to increased oxidative stress, due to constant
hyperglycaemia [29–31], it should be expected an increase
in Ca2 +-dependent MPT induction during diabetes [32].
However, mitochondria isolated from STZ-treated rats liver
[5] and from GK rats heart [6] presented a lower suscepti-
bility to MPT induction in the presence of Ca2 +. These
observations were on the basis of the present study, designed
to evaluate differences in MPT susceptibility due to diabetes
in liver mitochondria. Our results showed that mitochondria
from diabetic rats were less susceptible to the induction of
MPTP assessed by Ca2 +/Pi. Surprisingly, we noted that thetar control rats. Mitochondrial cardiolipin content was quantified using an
methods. Data are meanF S.E. of five different mitochondrial preparations.
< 0.01 as compared to Wistar 13 weeks of age (3 weeks after treatment with
with STZ).
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betes time length and severity, as observed in STZ-treated
rats after 9 weeks of treatment and GK rats 20 weeks of age.
These observations were even more surprising since the
levels of endogenous oxidation products in these mitochon-
dria and in liver mitochondria from STZ-treated rats 3 weeks
after treatment were lower when compared to controls
[evaluated as thiobarbituric acid reactive substances
(TBARS) formation [33]; data not shown].
In order to find some explanations for the observed
results, we evaluated the CoQ content in liver mitochondria.
It is well known that oxidative stress can trigger the MPT
pore opening [32,34]. Coenzyme Q acts as an electron carrier
from mitochondrial respiratory complexes I and II to com-
plex III; also, CoQ in its fully reduced form (ubiquinol) is a
potent antioxidant [35–38], preventing lipid peroxidation.
Furthermore, as ubiquinone-binding site regulates the MPT
pore [39], an increase in CoQ contents (CoQ0 and, probably,
also CoQ9 and CoQ10) may enhance the calcium retention
capacity in mitochondria [3]. Our results showing that the
amount of CoQ was significantly increased in liver mito-
chondria from diabetic rats suggest that this increase in CoQ
contents can, in part, be responsible for the decreased
susceptibility for MPTP opening, observed in diabetic mi-
tochondrial preparations (in addition to the increase in the
activity of Complexes II and IVof the respiratory chain [40]).
Additionally, the increase in CoQ contents in diabetic rats
can be responsible for the higher membrane potential devel-
oped upon energization with succinate; we also found an
increase in Complex II (and IV) specific activity with
increase in diabetes severity [40].
It has also been found that the membrane lipid composi-
tion is able to modulate the MPTP opening [26]. Cardiolipin
(diphosphatidylglycerol), the only phospholipid synthesized
by the mitochondria [26], has been proposed to regulate the
induction of MPT due to its ability to bind calcium [41–43],
owing to its strongly negatively charged headgroups. The
increased pool of negatively charges is thought to nonspe-
cifically bind Ca2 +, preventing its action on protein sites that
play a role in MPTP opening. Our data indicated that the
content in cardiolipin was significantly increased in diabetic
mitochondrial preparations (except for STZ-treated rats 3
weeks after treatment), when compared to Wistar mitochon-
dria, suggesting that mitochondria have the capacity to
enhance the synthesis of cardiolipin or adjust phospholipid
metabolism, in order to decrease the susceptibility to the
induction of MPT. The higher content in cardiolipin of the
IMM of diabetic rats makes it more impermeable to protons
(and other ions), which could explain the higher values of
DW observed.
The higher calcium loading capacity in diabetic rats may
interfere with the normal calcium pathways of the cell.
Inside mitochondria, calcium can stimulate some dehydro-
genases (pyruvate dehydrogenase, isocitrate dehydrogenase
and 2-oxoglutarate dehydrogenase [44,45]) and have a
regulatory effect on ATP synthase [46].Previous reports from our group [6,47,48] on the sus-
ceptibility on heart and brain mitochondrial preparations to
MPTP induction showed that GK mitochondrial prepara-
tions from heart had reduced susceptibility to MPT induc-
tion [6], in agreement with the liver mitochondria results
reported in this study, while heart mitochondria isolated
from STZ-treated rats after 3 weeks of treatment had an
increase susceptibility to the induction of MPT [47]. Brain
mitochondria isolated from STZ rats after 9 weeks of
treatment were less susceptible to MPT induction.
In conclusion, our results suggest that liver mitochon-
dria isolated from diabetic rats presented some metabolic
adjustments, namely increase in CoQ and membrane car-
diolipin contents that can be responsible for the observed
decrease in the susceptibility to MPT induction in the
presence of Ca2. These adjustments seem to vary between
the tissues studied in our lab (liver, brain and heart). We
cannot exclude the possibility that liver mitochondria from
control rats present a higher number of spontaneous (but
reversible) MPTP openings, compared to diabetic liver
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